Literature DB >> 2469015

Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia.

N P Roos1, J E Wennberg, D J Malenka, E S Fisher, K McPherson, T F Andersen, M M Cohen, E Ramsey.   

Abstract

As part of an ongoing effort to evaluate alternative treatments for benign prostatic hyperplasia, we compared the outcomes of transurethral resection of the prostate with those of open prostatectomy. Men undergoing prostatectomy in Denmark (n = 36,703), Oxfordshire, England (n = 5284), and Manitoba, Canada (n = 12,090), were identified retrospectively through administrative data and followed for up to eight years. The cumulative percentage of patients undergoing a second prostatectomy was substantially higher after transurethral than after open prostatectomy (12.0 vs. 4.5 percent in Denmark, 12.0 vs. 1.8 percent in Oxfordshire, and 15.5 vs. 4.2 percent in Manitoba). The long-term age-specific mortality rates associated with transurethral prostatectomy as compared with open prostatectomy were also elevated in each country. The data on 1650 Canadian patients were used to investigate the contribution of coexisting morbid conditions to the elevated risk of death. The relative risk was 1.45 (95 percent confidence interval, 1.15 to 1.83) before risk adjustment and 1.45 (95 percent confidence interval, 1.15 to 1.84) after adjustment; the higher mortality was seen among low-risk as well as high-risk patients. These findings suggest that transurethral prostatectomy is less effective in overcoming urinary obstruction than the open operation. Our data also raise the possibility that transurethral prostatectomy may result in higher long-term mortality, although we cannot rule out potential confounding effects of unmeasured characteristics of patients.

Entities:  

Mesh:

Year:  1989        PMID: 2469015     DOI: 10.1056/NEJM198904273201705

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  85 in total

Review 1.  Review of current and future approaches to the management of benign prostatic hyperplasia.

Authors:  J C Gingell
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

2.  Reprocessing data to form QALYs.

Authors:  J Coast
Journal:  BMJ       Date:  1992-07-11

3.  Outcomes and the management of health care. Health Services Research Group.

Authors: 
Journal:  CMAJ       Date:  1992-12-15       Impact factor: 8.262

Review 4.  Evaluating prognostic factors: implications for measurement of health care outcome.

Authors:  M C Gulliford
Journal:  J Epidemiol Community Health       Date:  1992-08       Impact factor: 3.710

5.  Laparoscopic or minilaparotomy cholecystectomy?

Authors:  J N Baxter; P J O'Dwyer
Journal:  BMJ       Date:  1992-02-29

Review 6.  Patient Outcomes Research Teams and the Agency for Health Care Policy and Research.

Authors:  M E Salive; J A Mayfield; N W Weissman
Journal:  Health Serv Res       Date:  1990-12       Impact factor: 3.402

7.  Overcoming potential pitfalls in the use of Medicare data for epidemiologic research.

Authors:  E S Fisher; J A Baron; D J Malenka; J Barrett; T A Bubolz
Journal:  Am J Public Health       Date:  1990-12       Impact factor: 9.308

Review 8.  Benign prostatic hyperplasia.

Authors:  A Melville; J Donovon; T Sheldon; T Peters
Journal:  Qual Health Care       Date:  1996-06

Review 9.  Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 10.  Technical aspects of holmium laser enucleation of the prostate for benign prostatic hyperplasia.

Authors:  Myong Kim; Hahn-Ey Lee; Seung-June Oh
Journal:  Korean J Urol       Date:  2013-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.